Work

7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)

Year: 2015

Type: article

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(16)31931-1

Authors: M.C. Pietanza, D. Spigel, T.M. Bauer, N.E. Ready, B.S. Glisson, D. Morgensztern, F. Robert, R. Salgia, M. Kochendorfer, M. Patel, D.K. Strickland, R. Govindan, H.A. Burris, C.M. Rudin, S. Dylla

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2341522992

FWCI: 2.081

Cites:

Cited by: 19

Related to: 10